Journal
SCIENCE SIGNALING
Volume 15, Issue 717, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.abj4743
Keywords
-
Categories
Funding
- Fondation pour la Recherche Medicale (FRM)
- Cole Foundation
- Fonds de la recherche en sante du Quebec (FRSQ)
- Canadian Cancer Society Research Institute
- Fonds de partenariat pour un Quebec innovant et en sante (FPQIS) of the Quebec government
- Genome Quebec PRIVAC
Ask authors/readers for more resources
Most patients with hepatocellular carcinoma (HCC) are diagnosed at a late stage with limited therapeutic options and poor prognosis. A previously uncharacterized oncogenic signaling pathway mediated by the tyrosine kinase Yes has been identified in HCC, providing a potential therapeutic target in this type of cancer. Yes activity was shown to be necessary for HCC cell proliferation, and its high activity predicted shorter overall survival in HCC patients.
Most patients with hepatocellular carcinoma (HCC) are diagnosed at a late stage and have few therapeutic options and a poor prognosis. This is due to the lack of clearly defined underlying mechanisms or a dominant oncogene that can be targeted pharmacologically, unlike in other cancer types. Here, we report the identification of a previously uncharacterized oncogenic signaling pathway in HCC that is mediated by the tyrosine kinase Yes. Using genetic and pharmacological interventions in cellular and mouse models of HCC, we showed that Yes activity was necessary for HCC cell proliferation. Transgenic expression of activated Yes in mouse hepatocytes was sufficient to induce liver tumorigenesis. Yes phosphorylated the transcriptional coactivators YAP and TAZ (YAP/TAZ), promoting their nuclear accumulation and transcriptional activity in HCC cells and liver tumors. We also showed that YAP/ TAZ were effectors of the Yes-dependent oncogenic transformation of hepatocytes. Src family kinase activation correlated with the tyrosine phosphorylation and nuclear localization of YAP in human HCC and was associated with increased tumor burden in mice. Specifically, high Yes activity predicted shorter overall survival in patients with HCC. Thus, our findings identify Yes as a potential therapeutic target in HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available